Tags

Type your tag names separated by a space and hit enter

Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease.
Respiration. 2013; 86(4):280-7.R

Abstract

BACKGROUND

Triple inhalation therapy with tiotropium (Tio) and salmeterol/fluticasone propionate combination (SFC) is widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, the effects of triple therapy on airway structural changes remain unknown.

OBJECTIVE

The aim of the study was to assess the effects of Tio, salmeterol (SM), SFC and Tio plus SFC on airway dimensions in COPD.

METHODS

A randomized, open-label, 4-way study (n = 60) was conducted comparing 16-week treatment periods of Tio (18 μg once daily), SM (50 μg twice daily), SFC (50/250 μg twice daily) and Tio (18 μg once daily) plus SFC (50/250 μg twice daily). Airway dimensions were assessed by a validated CT technique, and airway wall area (WA) corrected for body surface area (BSA), percentage WA (WA%), wall thickness/√BSA and luminal area (Ai)/BSA at the right apical segmental bronchus were measured. Pulmonary function and the St. George's Respiratory Questionnaire (SGRQ) were evaluated.

RESULTS

Tio plus SFC resulted in a significant decrease in WA corrected for BSA and WA% compared with Tio, SM and SFC (p < 0.05 for all). The changes in WA% and Ai/BSA were significantly correlated with changes in forced expiratory volume in 1 s (r = -0.86, p < 0.001, and r = 0.48, p < 0.05, respectively). There were more significant improvements in SGRQ scores after treatment with triple therapy than after the 3 other treatments.

CONCLUSIONS

Tio plus SFC therapy is more effective than Tio, SM and SFC for reducing airway wall thickness in COPD.

Authors+Show Affiliations

Department of Respiratory Medicine, Atami Hospital, International University of Health and Welfare, Atami, Japan.No affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

23880883

Citation

Hoshino, Makoto, and Junichi Ohtawa. "Effects of Tiotropium and Salmeterol/fluticasone Propionate On Airway Wall Thickness in Chronic Obstructive Pulmonary Disease." Respiration; International Review of Thoracic Diseases, vol. 86, no. 4, 2013, pp. 280-7.
Hoshino M, Ohtawa J. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease. Respiration. 2013;86(4):280-7.
Hoshino, M., & Ohtawa, J. (2013). Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease. Respiration; International Review of Thoracic Diseases, 86(4), 280-7. https://doi.org/10.1159/000351116
Hoshino M, Ohtawa J. Effects of Tiotropium and Salmeterol/fluticasone Propionate On Airway Wall Thickness in Chronic Obstructive Pulmonary Disease. Respiration. 2013;86(4):280-7. PubMed PMID: 23880883.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease. AU - Hoshino,Makoto, AU - Ohtawa,Junichi, Y1 - 2013/07/20/ PY - 2012/07/13/received PY - 2013/04/03/accepted PY - 2013/7/25/entrez PY - 2013/7/25/pubmed PY - 2014/8/13/medline SP - 280 EP - 7 JF - Respiration; international review of thoracic diseases JO - Respiration VL - 86 IS - 4 N2 - BACKGROUND: Triple inhalation therapy with tiotropium (Tio) and salmeterol/fluticasone propionate combination (SFC) is widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, the effects of triple therapy on airway structural changes remain unknown. OBJECTIVE: The aim of the study was to assess the effects of Tio, salmeterol (SM), SFC and Tio plus SFC on airway dimensions in COPD. METHODS: A randomized, open-label, 4-way study (n = 60) was conducted comparing 16-week treatment periods of Tio (18 μg once daily), SM (50 μg twice daily), SFC (50/250 μg twice daily) and Tio (18 μg once daily) plus SFC (50/250 μg twice daily). Airway dimensions were assessed by a validated CT technique, and airway wall area (WA) corrected for body surface area (BSA), percentage WA (WA%), wall thickness/√BSA and luminal area (Ai)/BSA at the right apical segmental bronchus were measured. Pulmonary function and the St. George's Respiratory Questionnaire (SGRQ) were evaluated. RESULTS: Tio plus SFC resulted in a significant decrease in WA corrected for BSA and WA% compared with Tio, SM and SFC (p < 0.05 for all). The changes in WA% and Ai/BSA were significantly correlated with changes in forced expiratory volume in 1 s (r = -0.86, p < 0.001, and r = 0.48, p < 0.05, respectively). There were more significant improvements in SGRQ scores after treatment with triple therapy than after the 3 other treatments. CONCLUSIONS: Tio plus SFC therapy is more effective than Tio, SM and SFC for reducing airway wall thickness in COPD. SN - 1423-0356 UR - https://www.unboundmedicine.com/medline/citation/23880883/Effects_of_tiotropium_and_salmeterol/fluticasone_propionate_on_airway_wall_thickness_in_chronic_obstructive_pulmonary_disease_ L2 - https://www.karger.com?DOI=10.1159/000351116 DB - PRIME DP - Unbound Medicine ER -